Johnson & Johnson has announced Week 48 results from the Phase 3 FUZION trial of TREMFYA (guselkumab) in adults with Crohn’s disease and perianal fistula. Combined fistula remis ...
ROI opportunities center on cloud and edge migration, AI/ML, digital twins and automation, supported by strong connectivity, SME grants and sovereign hosting.Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results